相关实验视频
Updated: May 24, 2025

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.6K
目前使用inclisiran治疗心血管疾病:当前临床试验概述
1Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Frontiers in pharmacology
|March 3, 2025
概括
在心血管疾病患者中,Inclisiran有效降低了LDL-C和PCSK9. 然而,需要更多关于心血管长期结果和组合治疗有效性的真实数据.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病是全球健康负担.
- 一个小干扰RNA (siRNA) 的Inclisiran,准PCSK9以减少LDL-C.
- 英克利西兰在治疗心血管疾病中的确切作用需要进一步阐明.
研究的目的:
- 审查目前在心血管疾病的背景下使用Inclisiran的情况.
- 分析临床试验数据关于Inclisiran在心血管疾病中的有效性和安全性.
主要方法:
- 对Clinicaltrials.gov进行了全面的搜索,寻找涉及Inclisiran和心血管疾病的研究.
- 数据提取的重点是研究设计,参与者数量,干预具体情况和结果.
- 分析了11项相关的临床试验.
主要成果:
- 对11项试验 (214,176名参与者) 的分析表明,Inclisiran具有良好的安全性和有效的LDL-C和PCSK9降低.
- 在加重剂量后每年两次给药是一种常见的治疗方案.
- 大多数研究主要评估LDL-C降低,仅限于直接心血管结果.
结论:
- 英克利西兰显示出显著的LDL-C降低能力.
- 目前,关于其对长期心血管结果的影响的证据有限.
- 需要进一步的实践研究来评估长期的安全性,坚持性,成本效益和组合治疗的好处.
相关概念视频
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
454
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
454
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437

